Mucosal SIV vaccines comprising inactivated virus particles and bacterial adjuvants induce CD8+ T-regulatory cells that suppress SIV-positive CD4+ T-cell activation and prevent SIV infection in the macaque model

Frontiers in Immunology

Volumn 5, Issue JUN, 2014, Pages

  Andrieu, Jean Marie ^a   Chen, Song ^b   Lai, Chunhui ^b   Guo, Weizhong ^b   Lu, Wei ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Bacterial adjuvants; BCG; HIV tolerogenic vaccine; HIV vaccine; Inactivated SIV; Lactobacilli; SIV replication; SIV vaccine

Indexed keywords

EID: 84905669844     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00297     Document Type: Article

References (63)

1. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol (2010) 7:1055-65. doi:10.1128/CVI.00131-10
2. Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (1983) 220(4599):868-71. doi:10.1126/science.6189183
3. Esparza J. A brief history of the global effort to develop a preventive HIV vaccine. Vaccine (2013) 31(35):3502-18. doi:10.1016/j.vaccine.2013.05.018
4. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 361:2209-20. doi:10.1056/NEJMoa0908492
5. Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, et al. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis (2012) 206(2):258-66. doi:10.1093/infdis/jis342
6. Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker LG, Churchyard G, et al. Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. Lancet Infect Dis (2014) 14(5):388-96. doi:10.1016/S1473-3099(14)70020-9
7. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med (2013) 369(22):2083-92. doi:10.1056/NEJMoa1310566
8. Fauci AS, Marovich MA, Dieffenbach CW, Hunter E, Buchbinder SP. Immunology. Immune activation with HIV vaccines. Science (2014) 344(6179):49-51. doi:10.1126/science.1250672
9. Andrieu JM, Even P, Venet A. AIDS and related syndromes as a viral-induced autoimmune disease of the immune system: an anti-MHC II disorder. Therapeutic implications. AIDS Res (1986) 2(3):163-74. doi:10.1089/aid.1.1986.2.163
10. Paiardini M, Müller-Trutwin M. HIV-associated chronic immune activation. Immunol Rev (2013) 254(1):78-101. doi:10.1111/imr.12079
11. Klatt NR, Chomont N, Douek DC, Deeks SG. Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev (2013) 254(1):326-42. doi:10.1111/imr.12065
12. Andrieu JM, Even P, Venet A, Tourani JM, Stern M, Lowenstein W, et al. Effects of cyclosporine on T-cell subsets in human immunodeficiency virus disease. Clin Immunol Immunopathol (1988) 46:181-98. doi:10.1016/0090-1229(88)90071-2
13. Levy R, Jais JP, Tourani JM, Even P, Andrieu JM. Long-term follow-up of HIV positive asymptomatic patients having received cyclosporine A. Adv Exp Med Biol (1995) 374:229-34. doi:10.1007/978-1-4615-1995-9_20
14. Andrieu JM, Lu W, Levy R. Sustained increases in CD4 cell counts in asymptomatic human immunodeficiency virus type 1-seropositive patients treated with prednisolone for 1 year. J Infect Dis (1995) 171(3):523-30. doi:10.1093/infdis/171.3.523
15. Andrieu JM, Lu W. Long-term clinical, immunologic and virologic impact of glucocorticoids on the chronic phase of HIV infection. BMC Med (2004) 2:17. doi:10.1186/1741-7015-2-17
16. Lu W, Salerno-Goncalves R, Yuan J, Sylvie D, Han DS, Andrieu JM. Glucocorticoids rescue CD4+ T-lymphocytes from activation-induced apoptosis triggered by HIV-1: implications for pathogenesis & therapy. AIDS (1995) 9:35-42. doi:10.1097/00002030-199501000-00005
17. Lu W, Andrieu JM. In vitro human immunodeficiency virus eradication by autologous CD8(+) T-cells expanded with inactivated-virus-pulsed dendritic cells. J Virol (2001) 75(19):8949-56. doi:10.1128/JVI.75.19.8949-8956.2001
18. Lu W, Wu X, Lu Y, Guo W, Andrieu JM. Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med (2003) 9:27-32. doi:10.1038/nm806
19. Lu W, Arraes LC, Ferreira WT, Andrieu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med (2004) 10:1359-65. doi:10.1038/nm1147
20. García F, Climent N, Guardo AC, Gil C, León A, Autran B, et al. A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci Transl Med (2013) 5(166):166ra2. doi:10.1126/scitranslmed.3004682
21. Chen S, Lai C, Wu X, Lu Y, Han D, Guo W, et al. Variability of bio-clinical parameters in Chinese-origin Rhesus macaques infected with simian immunodeficiency virus: a nonhuman primate AIDS model. PLoS One (2011) 6:e23177. doi:10.1371/journal.pone.0023177
22. Stahl-Hennig C, Suh YS, Park KS, Sauermann U, Kim KS, Ahn S, et al. Immunogenicity of a DNA prime and recombinant adenovirus boost regime significantly varies between rhesus macaques of Chinese and Indian origins. J Med Primatol (2007) 36:195-205. doi:10.1111/j.1600-0684.2007.00237.x
23. Lu W, Chen S, Lai C, Guo W, Fu L, Andrieu JM. Induction of CD8+ regulatory T-cells protects macaques against SIV challenge. Cell Rep (2012) 2(6):1736-46. doi:10.1016/j.celrep.2012.11.016
24. Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, Fine PE, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis (2014) 58(4):470-80. doi:10.1093/cid/cit790
25. Ramoner R, Rieser C, Herold M, Klocker H, Bartsch G, Stenzl A, et al. Activation of human dendritic cells by bacillus Calmette-Guerin. J Urol (1998) 159(5):1488-92. doi:10.1097/00005392-199805000-00021
26. Demangel C, Britton WJ. Interaction of dendritic cells with mycobacteria: where the action starts. Immunol Cell Biol (2000) 78:318-24. doi:10.1046/j.1440-1711.2000.00935.x
27. Gandhi NM, Morales A, Lamm DL. Bacillus Calmette-Guérin immunotherapy for genitourinary cancer. BJU Int (2013) 112(3):288-97. doi:10.1111/j.1464-410X.2012.11754.x
28. Stewart JH IV, Levine EA. Role of bacillus Calmette-Guérin in the treatment of advanced melanoma. Expert Rev Anticancer Ther (2011) 11(11):1671-6. doi:10.1586/era.11.163
29. Benévolo-de-Andrade TC, Monteiro-Maia R, Cosgrove C, Castello-Branco LR. BCG Moreau Rio de Janeiro - an oral vaccine against tuberculosis - review. Mem Inst Oswaldo Cruz (2005) 100(5):459-65. doi:10.1590/S0074-02762005000500002
30. Grangette C, Nutten S, Palumbo E, Morath S, Hermann C, Dewulf J. Enhanced anti-inflammatory capacity of a Lactobacillus plantarum mutant synthesizing modified teichoic acids. Proc Natl Acad Sci USA (2005) 102:10321-6. doi:10.1073/pnas.0504084102
31. van Baarlen P, Troost FJ, van Hemert S, van der Meer C, de Vos WM, de Groot PJ, et al. Differential NF-kappa B pathways induction by Lactobacillus plantarum in the duodenum of healthy humans correlating with immune tolerance. Proc Natl Acad Sci U S A (2009) 106:2371-6. doi:10.1073/pnas.0809919106
32. Baba N, Samson S, Bourdet-Sicard R, Rubio M, Sarfati M. Commensal bacteria trigger a full dendritic cell maturation program that promotes the expansion of non-Tr1 suppressor T-cells. J Leukoc Biol (2008) 84:1468-76. doi:10.1189/jlb.0108017
33. Kleerebezem M, Boekhorst J, van Kranenburg R, Molenaar D, Kuipers OP, Leer R. Complete genome sequence of Lactobacillus plantarum WCFS1. Proc Natl Acad Sci USA (2003) 100:1990-5. doi:10.1073/pnas.0337704100
34. Nivoliez A, Camares O, Paquet-Gachinat M, Bornes S, Forestier C, Veisseire P. Influence of manufacturing processes on in vitro properties of the probiotic strain Lactobacillus rhamnosus Lcr35®. J Biotechnol (2012) 160(3-4):236-41. doi:10.1016/j.jbiotec.2012.04.005
35. Faria AM, Weiner HL. Oral tolerance. Immunol Rev (2005) 206:232-59.
36. Aandahl EM, Michaelsson J, Moretto WJ, Hecht FM, Nixon DF. Human CD4+ CD25+ regulatory T-cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol (2004) 78:2454-9. doi:10.1128/JVI.78.5.2454-2459.2004
37. Nilsson J, Boasso A, Velilla PA, Zhang R, Vaccari M, Franchini G, et al. HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood (2006) 108:3808-17. doi:10.1182/blood-2006-05-021576
38. Card CM, McLaren PJ, Wachihi C, Kimani J, Plummer FA, Fowke KR. Decreased immune activation in resistance to HIV-1 infection is associated with an elevated frequency of CD4(+)CD25(+)FOXP3(+) regulatory T-cells. J Infect Dis (2009) 199:1318-22. doi:10.1086/597801
39. Chase AJ, Yang HC, Zhang H, Blankson JN, Siliciano RF. Preservation of FoxP3+ regulatory T-cells in the peripheral blood of human immunodeficiency virus type 1-infected elite suppressors correlates with low CD4+ T-cell activation. J Virol (2008) 82:8307-15. doi:10.1128/JVI.00520-08
40. Kornfeld C, Ploquin MJ, Pandrea I, Faye A, Onanga R, Apetrei C, et al. Anti-inflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS. J Clin Invest (2005) 115:1082-91. doi:10.1172/JCI200523006
41. Kim HJ, Verbinnen B, Tang X, Lu L, Cantor H. Inhibition of follicular T-helper cells by CD8(+) regulatory T-cells is essential for self tolerance. Nature (2010) 467:328-32. doi:10.1038/nature09370
42. Sarantopoulos S, Lu L, Cantor H. Qa-1 restriction of CD8+ suppressor T-cells. J Clin Invest (2004) 114:1218-21. doi:10.1172/JCI200423152
43. Pietra G, Romagnani C, Manzini C, Moretta L, Mingari MC. The emerging role of HLA-E-restricted CD8+ T-lymphocytes in the adaptive immune response to pathogens and tumors. J Biomed Biotechnol (2010) 2010:907-14. doi:10.1155/2010/907092
44. Kim HJ, Wang X, Radfar S, Sproule TJ, Roopenian DC, Cantor H. CD8+ T regulatory cells express the Ly49 Class I MHC receptor and are defective in autoimmune prone B6-Yaa mice. Proc Natl Acad Sci U S A (2011) 108:2010-5. doi:10.1073/pnas.1018974108
45. Nagarajan NA, Gonzalez F, Shastri N. Nonclassical MHC class Ib-restricted cytotoxic T-cells monitor antigen processing in the endoplasmic reticulum. Nat Immunol (2012) 13:579-86. doi:10.1038/ni.2282
46. Jiang H, Canfield SM, Gallagher M, Jiang HH, Jiang Y, Zheng Z, et al. HLA-E-restricted regulatory CD8(+) T-cells are involved in development and control of human autoimmune type 1 diabetes. J Clin Invest (2010) 120:3641-50. doi:10.1172/JCI43522
47. Sacha JB, Chung C, Rakasz EG, Spencer SP, Jonas AK, Bean AT. Gag-specific CD8+ T-lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J Immunol (2007) 178:2746-54. doi:10.4049/jimmunol.178.5.2746
48. Sacha JB, Chung C, Reed J, Jonas AK, Bean AT, Spencer SP, et al. Pol-specific CD8+ T-cells recognize simian immunodeficiency virus-infected cells prior to Nef-mediated major histocompatibility complex class I down regulation. J Virol (2007) 81:11703-12. doi:10.1128/JVI.00926-07
49. Korin YD, Zack JA. Nonproductive human immunodeficiency virus type 1 infection in nucleoside-treated G0 lymphocytes. J Virol (1999) 73:6526-32.
50. Zack JA, Arrigo S, Weitsman SR, Go AS, Haislip A, Chen IS. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell (1990) 61:213-22.
51. Vatakis DN, Kim S, Kim N, Chow SA, Zack JA. Human immunodeficiency virus integration efficiency and site selection in quiescent CD4+ T-cells. J Virol (2009) 83:6222-33. doi:10.1128/JVI.00356-09
52. Haase AT. Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu Rev Med (2012) 62:127-39. doi:10.1146/annurev-med-080709-124959
53. Zhang Z, Wietgrefe SW, Li Q, Shore MD, Duan L, Reilly C, et al. Roles of substrate availability and infection of resting and activated CD4+ T-cells in transmission and acute simian immunodeficiency virus infection. Proc Natl Acad Sci U S A (2004) 101:5640-5. doi:10.1073/pnas.0308425101
54. Antas PR, Castello-Branco LR. New vaccines against tuberculosis: lessons learned from BCG immunization in Brazil. Trans R Soc Trop Med Hyg (2008) 102(7):628-30. doi:10.1016/j.trstmh.2008.03.014
55. Menzies D. What does tuberculin reactivity after bacille Calmette- Guérin vaccination tell us? Clin Infect Dis (2000) 31(Suppl 3):S71-4. doi:10.1086/314075
56. Hoft DF, Brown RM, Belshe RB. Mucosal bacille Calmette-Guérin vaccination of humans inhibits delayed-type hypersensitivity to purified protein derivative but induces mycobacteria-specific interferon-gamma responses. Clin Infect Dis (2000) 30(Suppl 3):S217-22. doi:10.1086/313864
57. Lee J, Reinke EK, Zozulya AL, Sandor M, Fabry Z. Mycobacterium bovis bacille Calmette-Guérin infection in the CNS suppresses experimental autoimmune encephalomyelitis and Th17 responses in an IFN-gamma-independent manner. J Immunol (2008) 181(9):6201-12. doi:10.4049/jimmunol.181.9.6201
58. Boer MC, van Meijgaarden KE, Joosten SA, Ottenhoff TH. CD8+ regulatory T-cells, and not CD4+ T-cells, dominate suppressive phenotype and function after in vitro live Mycobacterium bovis-BCG activation of human cells. PLoS One (2014) 9(4):e94192. doi:10.1371/journal.pone.0094192
59. Sheil B, Shanahan F, O'Mahony L. Probiotic effects on inflammatory bowel disease. J Nutr (2007) 137(3 Suppl 2):819S-24S.
60. Smits HH, Engering A, van der Kleij D, de Jong EC, Schipper K, van Capel TM, et al. Selective probiotic bacteria induce IL-10-producing regulatory T-cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J Allergy Clin Immunol (2005) 115(6):1260-7. doi:10.1016/j.jaci.2005.03.036
61. Scott CL, Aumeunier AM, Mowat AM. Intestinal CD103+ dendritic cells: master regulators of tolerance? Trends Immunol (2011) 32(9):412-9. doi:10.1016/j.it.2011.06.003
62. Chapman R, Chege G, Shephard E, Stutz H, Williamson AL. Recombinant Mycobacterium bovis BCG as an HIV vaccine vector. Review. Curr HIV Res (2010) 8(4):282-98. doi:10.2174/157016210791208686
63. Xin KQ, Hoshino Y, Toda Y, Igimi S, Kojima Y, Jounai N, et al. Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env. Blood (2003) 102(1):223-8. doi:10.1182/blood-2003-01-0110